PHV-wordings
Here you will find safety-relevant information that must be implemented in the corresponding product information due to a PHV issues.
Due to the relaunch of the EMA website in December 2023, you will find the current links to the entries prior to December 01, 2023 at https://www.ema.europa.eu
Search narrowed by
Rivastigmine
PSUR-outcome
|
07/01/2025
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Chlorphenamine maleate / Paracetamol New
PSUR-outcome
|
07/01/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Lanthanum New
PSUR-outcome
|
07/01/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Oxycodone New
PSUR-outcome
|
07/01/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Sugammadex
PSUR-outcome
|
19/12/2024
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Terazosin
PSUR-outcome
|
27/11/2024
Further information and amendments to the product information in all EU languages are available on the EMA website.
Mesalazine
PSUR-outcome
|
25/11/2024
Further information and amendments to the product information in all EU languages are available on the EMA website.
Zofenopril
PSUR-outcome
|
25/11/2024
Further information and amendments to the product information in all EU languages are available on the EMA website.
Amiodarone
PSUR-outcome
|
22/11/2024
Further information and amendments to the product information in all EU languages are available on the EMA website.
Levonorgestrel/Ethinylestradiol, Ethinylestradiol (combination pack)
PSUR-outcome
|
14/11/2024
Further information and amendments to the product information in all EU languages are available on the EMA website.
